Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?
Pfizer is out of favor right now, and for good reason, but dividend investors may want to take the risk just the same.
Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?
Overview
Eli Lilly (NYSE: LLY) is basically hitting it out of the park right now. Sales of its industry-leading GLP-1 weight-loss drugs Mounjaro and Zepbound rose 125% and 80%, respectively, in the first quarter of 2026, driving a huge 56% sales gain for the drug giant. There's a reason why the stock is up more than 400% over the past five years.
There's just one small problem for dividend investors: Eli Lilly's dividend yield is a tiny 0.6%. That's well below the S&P 500 index's (SNPINDEX: ^GSPC) roughly 1% yield and the average drug stock's 1.6%. Eli Lilly competitor Pfizer (NYSE: PFE) has a 6.6% yield, which is more than 10x higher! Is it the better dividend stock?
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
